INNATE AND ADAPTIVE IMMUNITY
The immune system is composed of innate and adaptive branches, which are nonspecific and specific, i.e. they target common and unique parts of non-self antigens, respectively (Table 1) . They discriminate between self and non-self, and activate appropriate effectors. Although innate and adaptive immunity appear independent, appropriate interactions between them are indispensable for the normal function of the immune response. Indeed, "mistakes" that happen in either branch can affect the organism as a whole.
Innate immunity is the first defense against invading pathogens and performs the function of immune surveillance (Calandra et al., 2003; Janeway, 2001) . Cells that constitute innate immunity are antigen-presenting cells (APC), including DC, macrophages and B cells. Innate immunity does not develop any antigen specificity because the discrimination between self and non-self is primarily based on pathogen associated molecular patterns (PAMP), which are common components of many microorganisms and are not found in humans, i.e. lipopolisacharides (LPS). Ligation of PAMP with toll-like receptors (TLR) on the surface of APC (Bachmann and Kopf, 2002; Takeda et al., 2003) leads to phagocytosis and APP. APP results in the presentation of processed antigens to T cells (Cresswell and Lanzavecchia, 2001) (Fig.1 ) and the establishment of adaptive immunity Smyth et al., 2001 ).
The function of adaptive immunity is the elimination of non-self antigens and the creation of immune memory. Constituents of adaptive immunity are B and T cells.
Adaptive immunity is unique and created only after the encounter with a specific non-self antigen, which is presented to them by APC. Discrimination between self and non-self at the level of adaptive immunity is complex and involves the elimination or functional inactivation of self-reactive lymphocytes from the repertoire. Establishment of adaptive immunity is slow, but once it is established, it is memorized and able to respond faster to subsequent contacts with the same antigen. However, since innate immunity is faster, it keeps infections under control until the establishment of adaptive immunity (Smyth et al., 2003) .
Very important role in APP, which connects innate and adaptive immunity, play the MHC determinants. Namely, processed antigenic peptides are presented to T cells only in the groove of MHC heterodimers.
MAJOR HISTOCOMPATIBILLITY COMPLEX DETERMINANTS
Genes that encode MHC determinants, also known as human leukocyte antigens (HLA), are located on the short arm of chromosome six and are extraordinary polymorphic (anonymous, 1999) . They are divided into two classes; MHC I and MHC II determinants that present intracellular and extracellular antigens, respectively. MHC I determinants are expressed on most nucleated cells, whereas MHC II determinants only on APC, mature B and activated T cells.
Three different MHC I determinants, namely HLA-A, HLA-B and HLA-C, are assembled and loaded with antigenic peptides, which are generated by protein degradation in the 26S proteasome, in the ER (Fruci et al., 2003; Saveanu et al., 2002) . The complex between MHC I heterodimer and antigenic peptide passes through the trans-Golgi network to the cell surface of APC and activates CD8+ T cells.
In humans, there are three classical MHC II determinants termed HLA-DP, HLA-DQ and HLA-DR, and two non-classical determinants named HLA-DM and HLA-DO (Fig. 2) . The former are cell surface heterodimers that present antigenic peptides, whereas the latter are cytoplasmic oligomers that are involved in loading of antigenic peptides. HLA-DP, HLA-DQ, HLA-DR and HLA-DM are composed of α and β chains, whereas HLA-DO form heterotetramers, composed of two α and two β chains (Fig. 2) . Classical MHC II determinants are assembled in the ER in the complex with the invariant chain (Ii), which stabilizes them and prevents premature loading of antigenic peptides. This complex is transported to the late endosome that contains degraded antigens. Loading of antigenic peptides is a three-step process (Fig. 2) . The first two steps, which take place in the late endosome, are the degradation and immediate replacement of Ii by the class II-associated Ii-chain peptide (CLIP). The third step happens in the MHC class II compartment (MIIC) and is the exchange of CLIP with antigenic peptides. This exchange is mediated by HLA-DM and is regulated by HLA-DO. The complex between MHC II determinants and antigenic peptides then travels to the surface of APC, where the antigen is presented to CD4+ T cells, which are the main regulators of the immune response.
Since they present antigens to CD4+ T cells, MHC II determinants are involved directly in the regulation of the immune response. Therefore, it is not surprising that the precise control of MHC II gene expression, which takes place at the level of transcription, is necessary for the equilibrated function of the immune system. Most of our knowledge about this control has been elucidated from studies of the severe combined immunodeficiency called MHC II deficiency or the type II bare lymphocyte syndrome (BLS) ( Table 2) .
BARE LYMPHOCYTE SYNDROME
BLS is an autosomal recessive disease characterized by the lack of constitutive and inducible MHC II gene expression (Table 2 ) (reviewd in (Reith and Mach, 2001 ) and (Nekrep et al., 2003) ). It is caused by mutations in factors that direct the transcription from MHC II promoters rather than in MHC II genes themselves.
More than ten years ago, transcription of MHC II genes was known to require several unidentified proteins. The earliest studies performed to identify these proteins employed in vitro assays, which revealed many irrelevant DNA-protein interactions. However, only genetic studies of BLS finally resolved this puzzle.
First, CIITA (Steimle et al., 1993) and regulatory factor X 5 (RFX5) (Steimle et al., 1995) were identified, which rescued the expression of MHC II determinants in complementation group (CG) A and C, respectively. Subsequently these findings led to the identification of regulatory factor X that contains ankyrin repeats (RFXANK/B) (Masternak et al., 1998; Nagarajan et al., 1999) and regulatory factor X associated protein (RFXAP) (Durand et al., 1997 ) that rescued the expression of MHC II determinants in CG B and D, respectively. These factors not only account for four CG of BLS, but also represent all gene-specific trans-acting factors that bind cis-acting elements for MHC II transcription.
cis-ACTING ELEMENTS
MHC II genes are transcribed from compact promoters (Fig. 3A) . They contain variable proximal promoter (PPS) and conserved upstream sequences (CUS) (reviewed in (Nekrep et al., 2003; Reith and Mach, 2001; Ting and Trowsdale, 2002) ).
In HLA-DRA PPS are located from position -52 to the transcription start site.
From the 5' direction, they contain octamer binding site (OBS) and initiator (Inr) sequences, but lack a functional TATA box. OBS binds the octamer binding protein-1 (Oct-1), which recruit the B cell octamer binding protein 1/Octamer binding factor 1/Oct coactivator from B cells (Bob1/OBF-1/OCAB) (Matthias, 1998) , whereas the initiator, which represents the transcription start site, binds RNA polymerase II associated transcription factor I (TF II I) and TATA binding protein (TBP) associated factor of 250 kDa (TAF II 250).
CUS are located from positions -139 to -67. From the 5' direction, they contain S, X and Y boxes. X box can be further divided into X1 and X2 boxes. Tight spatial constraints are preserved between these boxes , which bind different trans-acting factors. S and X1 boxes bind RFX (Table 2) (Jabrane- Ting and Trowsdale, 2002) , the X2 box binds X2 binding protein (X2BP), which can be c-AMP responsive element binding protein (CREBP) or activator protein 1 (AP-1) (Moreno et al., 1997; Setterblad et al., 1997 ) and the Y box binds nuclear factor Y (NF-Y) ( Table 2 ) (Maity and de Crombrugghe, 1998; Mantovani, 1999) .
However, PPS and CUS are not sufficient for HLA-DRA gene expression. A distal locus control region (LCR), which is located approximately 2.4 kb upstream of the CUS, is needed for efficient transcription from the HLA-DRA promoter in the organism (Masternak et al., 2003) (Fig. 3) . LCR is a mirror image of CUS. It contains S', X1', X2' and Y' boxes, but in the opposite orientation from the promoter. Indeed, the LCR binds the same trans-acting factors as the CUS.
trans-ACTING FACTORS
Several trans-acting factors are required for MHC II transcription (Fig. 4) . Among them, RFX and NF-Y create the platform for other co-activators to access MHC II promoters.
NF-Y is composed of three subunits (Table 2) (reviewd in (Matuoka and Yu Chen, 1999) ). NF-YA contains 374 residues. At the N-terminus of NF-YA, there is glutamine-rich region, which is followed by a stretch of prolines, serines and threonines. Its subunit interaction and DNA binding domains (DBD) are at the Cterminus.
NF-YB contains 207 residues. They form a histone fold and TATA-binding protein (TBP) binding domains. The histone fold is similar to that of histones 2A and 2B (Mantovani, 1999) , which is responsible for their dimerization. This domain has the same function in the assembly of NF-Y.
NF-YC contains 335 residues. As with NF-YB, it contains a histone fold and TBP binding domains, and in addition, a glutamine-rich region.
RFX is also composed of three subunits (Table 2 ) (reviewd in (Reith and Mach, 2001) ). RFXANK/B contains 260 residues that form an acidic domain and four ankyrin repeats, which gave it its name. RFX5 contains 616 residues, which form DBD and PEST domains. It is the 5th member of the RFX family that binds S and X boxes of MHC II promoters, which gave it its name. RFXAP contains 272 residues. This protein has acidic, basic and glutamine-rich domains. Because it interacts directly with RFX5, it was named the RFX associated protein.
Transcription from MHC II promoters starts after productive interactions between cis-acting elements and trans-acting factors, which lead to the formation of the MHC II enhanceosome and transcriptosome.
MHC II ENHANCEOSOME AND TRANSCRIPTOSOME
The MHC II enhanceosome is formed on CUS and LCR. Its assembly requires specific protein-protein and DNA-protein interactions. The formation of the enhanceosome starts off DNA ( NF-Y not only interacts with RFX, but also with different histone acetyltransferases (HAT) that make chromatin accessible for other co-activators (Fontes et al., 1999; Harton et al., 2001 ). Moreover, NF-YB and NF-YC bind TBP in vitro. This interaction helps to attract general transcription factors (GTF) to promoters, which lack a TATA box. The X2 box is bound by CREBP or AP-1 (Moreno et al., 1995; Setterblad et al., 1997) .
The very last step is the recruitment of CIITA to the MHC II enhanceosome, which converts it into the MHC II transcriptosome (Fig. 5 ). Once the transcriptosome is formed MHC II genes can be transcribed.
CLASS II TRANSACTIVATOR
CIITA is the master regulator of MHC II gene expression. Except for CIITA, all trans-acting factors that are needed for the transcription of MHC II genes are expressed ubiquitously. Thus, the synthesis of MHC II determinants correlates directly with the presence of CIITA, which is expressed constitutively only in DC and mature B cells and is inducible in most other cell types. After CIITA is recruited to the MHC II enhanceosome, it recruits the general transcriptional machinery.
CIITA contains 1130 residues (Fig. 7) . It can be divided into several domains, which are the N-terminal activation (AD), proline/serine/threonine rich (PST) and GTP binding domains (GBD), as well as the C-terminal leucine rich region (LRR). Additionally, CIITA contains three nuclear localization signals (NLS) and two putative nuclear export sequences (NES) (Fig. 7) .
The optimal AD of CIITA spans the first 322 residues. Its amino terminal part is rich in aspartic and glutamic acids and resembles the classical acidic AD, similar to that of VP16. Indeed, it can be replaced by AD from VP16 (herpes simplex) and E1a (adenovirus) (Riley and Boss, 1993) . Between residues 145 and 322 is the PST domain. As its name implies, it contains several prolines, serines and threonines that are targets for post-translational modifications. A consensus PEST sequence is located from positions 283 to 308, but it does not represent a degradation motif or degron (Schnappauf et al., 2003) . Rather, degrons are located within the first 99 residues and from positions 230 to 260 of CIITA, respectively (Schnappauf et al., 2003) .
A putative GBD resides downstream of AD, from positions 420 to 561. In contrast with the classical GBD, which contain four GTP-interacting sequences, CIITA contains only three (Harton et al., 1999) . These are Walker type A motif (G1), magnesium coordination site (G3) and a site that confers specificity for guanosine (G4). Indeed, although CIITA binds GTP, it does not hydrolyse it in vitro (Harton et al., 1999) . This finding suggests that CIITA might be a constitutively active GTP-binding protein. As mutations of either motif reduce the activity of CIITA, the sole function of GTP binding to CIITA may be to alter its conformation.
Five or six consensus LRR are located from positions 988 to 1097 (Harton et al., 2002) . They bind a 33 kDa protein of unknown function (Hake et al., 2000) .
Certain mutations positioned in α helices of LRR, but not in β sheets decrease the activity of CIITA. An additional LRR flanking the GBD might be involved in the aggregation of CIITA (Linhoff et al., 2001 ).
In CIITA, three NLS and two NES have been described. A bipartite NLS is located from positions 141 to 159, and two additional NLS were mapped from positions 405 to 414 next to G1 and 940 to 963 in the LRR Cressman et al., 2001; Nekrep et al., 2002; Spilianakis et al., 2000) . NES have been poorly characterized. The first is located in the first 114 residues, the second from positions 408 to 550 (Kretsovali et al., 2001 ). However, none of these NLS and NES have been examined directly.
REGULATION OF CIITA GENE EXPRESSION
Since the transcription of MHC II genes is dependent on the presence of CIITA, it is not surprising that its expression is highly regulated. In general, there are two types of regulation of gene expression: genetic and epigenetic. CIITA employs both. Whereas specific activators dictate active transcription, epigenetic silencing occurs via chromatin condensation.
Transcription of CIITA can be initiated from up to three different promoters: PI, PIII and PIV ( (Nickerson et al., 2001 ) and most likely represents a new protein-protein interaction domain. It also has the highest transcriptional activity (Nickerson et al., 2001 ). Importantly, a single mutation of a conserved leucine in CARD abrogates the activity of CIITA (Nickerson et al., 2001 ).
Epigenetic regulation of CIITA gene expression is utilized for embryonic survival. Notably, immune responses against paternal antigens in the placenta cause fetal death. In these tissues, promoter hypermethylation and histone deacetylation are proposed mechanisms for silencing the transcription of CIITA (Holtz et al., 2003; Morris et al., 2000; van den Elsen et al., 2000) . Derepression of CIITA transcription in trophoblasts after treatment with methylation inhibitors and trichostatin A with IFN-γ supports this mechanism.
In immature DC, the expression of CIITA is observed from PI, but it does not lead to APP. Phagocytosis of an antigen leads to the maturation of DC, which is accompanied by the cessation of further phagocytosis and repression of de novo CIITA and MHC II transcription and up-regulation of APP (Cella et al., 1997; Landmann et al., 2001; Pierre et al., 1997; Turley et al., 2000) . These events might be mediated by TLR. Because only the specific population of encountered antigens are processed and presented to T cells, such regulation could represent the best way of establishing adaptive immunity. Because the expression of CIITA is shut down after the clearance of a foreign antigen, it also lowers the chance of DC randomly presenting self-antigens.
In B cells, the constitutive expression of CIITA from PIII is accompanied by the presence of high levels of MHC II determinants on the cell surface. However, after B cells differentiate into highly specialized antibody producing plasma cells, the expression of CIITA and MHC II determinants is lost (Chen et al., 2002) . B lymphocyte inhibitory maturation protein 1 (BLIMP1) begins the process of this silencing (Piskurich et al., 2000) .
CIITA gene expression can be induced with IFN-γ from PI and PIV. PIV contains gamma-activated sites (GAS), which bind the signal transducer and activator of transcription 1 (STAT1) and an interferon regulatory factor-1 binding site, which binds interferon regulatory factor-1 (IRF-1) (Muhlethaler-Mottet et al., 1998).
Since PI is also responsive to IFN-γ, it could contain the same elements. After stimulation with IFN-γ, activated, phosphorylated STAT 1 translocates into the nucleus and binds GAS. Activated STAT 1 also induces the expression and accumulation of IRF-1. Binding of STAT 1 to GAS itself causes a weak acetylation of histones 3 and 4 in PIV (Morris et al., 2002) . However, the hyperacetylation of histones, which makes transcription more efficient, happens only after the accumulation and binding of IRF-1 to its site. 
POST-TRANSLATIONAL MODIFICATIONS OF CIITA
CIITA is post-translationaly modified by acetylation, phosphorylation and ubiquitylation (Fig. 8) . Effects of these modifications are complex and far from being clearly understood, but a general picture can be drawn from several studies.
The fate of CIITA in the cell is not random, but each step, starting after its translation and ending with its possible degradation, is regulated precisely by the following modifications.
Phosphorylation is the first post-translational modification of CIITA. Two studies have shown that this modification increases the activity of CIITA. The first study mapped phosphorylation sites into the PST region from positions 253 to 321 . The second study showed that protein kinase A (PKA) phosphorylates CIITA on one or more serines in the region between PST and GBD (Sisk et al., 2003) . The phosphorylation of CIITA leads to its accumulation, oligomerization and nuclear translocation. Most likely, these latter events happen because the phosphorylation changes the conformation of CIITA and exposes its NLS.
After it translocates into the nucleus, CIITA is acetylated on lysines 141 and 144, by CBP/p300 and also by pCAF, which are located in the nucleus (Spilianakis et al., 2000) . Acetylation of these residues keeps CIITA in the nucleus and increases the stability of the MHC II transcriposome. Acetylation might also facilitate the subsequent ubiquitylation of CIITA. Indeed, recent data suggest that histone deacetylases (HDAC) are involved in the ubiquitylation of CIITA .
Ubiquitylation, which is a covalent modification of lysines, plays an important role in transcription. Monoubiquitylated transcription factors tend to be more potent activators, whereas polyubiquitylated proteins are destined for degradation by the 26S proteasome. The role of ubiquitylation of CIITA has been addressed in two studies, but clear conclusions on the function of ubiquitin cannot be reached.
In the first study, monoubiquitin fused to CIITA prevented the degradation of the modified CIITA protein, but did not affect its transcriptional activity (Schnappauf et al., 2003) . In the second study, CIITA co-expressed with ubiquitin had a higher activity than CIITA alone, which was even more pronounced if ubiquitin could not form oligomers . This effect of ubiquitin was on the stabilization of the MHC II transcriptosome rather than on transcription itself. Interestingly, the same study showed that HDAC prevent the ubiquitylation of CIITA.
Phosphorylation also completes the post-translational modifications of CIITA.
Interestingly, PKA inactivates CIITA with phosphorylation of serines 834 and 1050. (Li et al., 2001) . Does this modification influence the stability of the enhanceosome? Does it lead to the degradation of CIITA, or does it expose the NES and enables the export of CIITA from the nucleus?
CIITA IS SHUTTLING PROTEIN
Transcription factors and co-factors need to be transported into the nucleus to perform their function. Nucleo-cytoplasmic shuttling usually requires two types of functionally unique signals, NLS and NES. CIITA contains both, but none of them have been examined adequately (Fig. 7) .
At steady state, CIITA is distributed equally between the nucleus and the cytoplasm. Mutant CIITA proteins, which do not follow this pattern, led to the identification of NLS. As mentioned earlier, two NLS are located at the Nterminus and one NLS in the C-terminus of CIITA (Fig. 7) , , (Spilianakis et al., 2000) . However, none of them has been examined directly, i.e. they have not been demonstrated to shuttle a heterologous protein. Moreover, binding to importins has not been investigated.
Two regions in the N-terminus of CIITA have been proposed to function as NES (Fig. 7) . The only support comes from interactions between these regions with the chromosomal region maintenance-1 (Crm-1) protein (Kretsovali et al., 2001 ).
Indeed, treatment with leptomycin B (LMB), which blocks Crm-1 dependent nuclear export (Kudo et al., 1998) , leads to the nuclear accumulation of CIITA Kretsovali et al., 2001 ). However, no consensus NES can be found within these sequences. In addition none of the five putative NES, three of which correspond perfectly to the consensus sequence [Lx(2,3)Lx(2,3)-LxL], functioned in a direct export nor bound Crm-1 (Drozina, Kohoutek, Peterlin, unpublished observation).
All these results imply the presence of other transport mechanism/s. Indeed, several additional regions of CIITA are involved in its nuclear localization, including GBD (Harton et al., 1999; Raval et al., 2003) and LRR (Hake et al., 2000; Harton et al., 2002; Towey and Kelly, 2002) . Moreover, some mutations in the LRR disrupt interaction between p33 and CIITA, which interferes with its nuclear localization (Hake et al., 2000) . Furthermore, it was suggested that NES from CIITA resemble that of snurportin-1, which is discontinuous (Paraskeva et al., 1999) . In this case, only after a conformational change can Crm-1 bind and transport snurportin-1 from the nucleus to the cytoplasm (Paraskeva et al., 1999) .
CIITA IS TRANSCRIPTIONAL INTEGRATOR
Once CIITA is modified appropriately and present in the nucleus, it can perform its function. It binds to the MHC II enhanceosome, attracts several transcription factors and co-factors and integrates initiation and elongation of transcription as well as chromatin remodeling into a process that finally results in the expression of MHC II genes. Moreover, CIITA might also be involved in the dissociation of the MHC II enhanceosome after the termination of transcription.
CIITA recruits RNA polymerase II (RNAPII) to MHC II promoters and increases rates of initiation and elongation of transcription. For the former function, interactions with TAF (Fontes et al., 1997) , TFIIB (Mahanta et al., 1997) and Bob1/OBF-1/OCAB might be necessary. For the latter, the interaction between CIITA and the positive transcription elongation factor b (PTEFb), which phosphorylates the CTD of RNAPII, is needed (Kanazawa et al., 2000) .
Not surprisingly, CIITA also recruits HAT and chromatin remodeling machinery to the HLA-DRA promoter. The AD of CIITA binds CBP/p300 (Fontes et al., 1999) , pCAF (Spilianakis et al., 2000) and Brahma-related gene 1 (BRG-1) (Mudhasani and Fontes, 2002) . In addition, it has been suggested that CIITA posseses intrinsic HAT activity Raval et al., 2001 ). This activity of CIITA has been mapped into AD and bears homology with other HAT domains, e.g. in CBP/p300 . Interestingly, CIITA that lacks its AD is still able to mediate the acetylation of histone 4, but not of histone 3 (Beresford and Boss, 2001 ). Thus, CIITA could contain another region with direct or indirect HAT activity.
After the termination of transcription, deacetylation of histones, which is mediated by HDAC, is involved in chromatin condensation. Binding of CIITA to HDAC1 and HDAC2 decreases the activity of CIITA, most probably because histone deacetylation disrupts the MHC II enhanceosome . Thus, CIITA might play an active role in the regulation of its own function on MHC II promoters.
CONCLUSIONS AND FUTURE DIRECTIONS
In the last few years, much research resulted in greater understanding of the function and regulation of CIITA. Since CIITA plays a major role in the regulation of the immune response via MHC II determinants, this is not surprising. Moreover, if one understood the "rules" of this regulation, one could use this knowledge for the manipulation of the immune system. However, many questions remain. Acetylation and ubiquitylation of CIITA are depicted as red Ac and Ub, respectively. NLS and NES stand for nuclear localization signal and nuclear export sequence, respectively. 
